Amber M D'Souza

Dr. Amber M D'Souza

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2020 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
PDF file
ADAmber M D'Souza
Amber M D'Souza
ATAlexander J Towbin
Alexander J Towbin
AGAnita Gupta
Anita Gupta
MAMaria Alonso
Maria Alonso
JNJaimie D. Nathan
Jaimie D. Nathan
JGJames I Geller
James I Geller
Background: Hepatocellular carcinoma (HCC) is often a chemoresistant neoplasm with a poor prognosis. Pediatric HCC may reflect unique biological and clinical heterogeneity.Procedure: An IRB‐approved retrospective institutional review of patients with HCC treated between 2004 and 2015 was undertaken. Clinical, radiographic, and histologic data were collected from all patients.Results: Thirty‐two patients with HCC, median age 11.5 years (range 1‐20) were identified. Seventeen patients had a genetic or anatomic predisposition. Histology was conventional HCC (25) and fibrolamellar HCC (7). Evans staging was 1 (12); 2 (1); 3 (10); 4 (9). Sixteen patients underwent resection at diagnosis and five patients after neoadjuvant chemotherapy. Surgical procedures included liver transplantation (LT, 11), hemihepatectomy (9), and segmentectomy (1). Eighteen patients had medical therapy (13 neoadjuvant, 5 adjuvant). Most common initial medical therapy included sorafenib alone (7) and cisplatin/doxorubicin‐based therapy (8). Overall, 14 (43.8%) patients survived with a median follow‐up of 58.8 months (range 26.5‐157.6). Cause of death was most often linked to lack of primary tumor surgery (11). Of the survivors, Evans stage was 1 (11), 2 (1), and 3 (2, both treated with LT). Four of 18 patients (22%) who received medical therapy, 8 of 17 patients with a predisposition (47%), and 14 of 21 patients (66%) who underwent surgery remain alive.Conclusions: Genetic and anatomic predisposing conditions were seen in over half of this cohort. Evans stage 1 or 2 disease was linked to improved survival. LT trended toward improved survival. Use of known chemotherapy agents may benefit a smaller group of pediatric HCC and warrants formal prospective study through cooperative group trials.

3 July 2018 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
ADAmber M D'Souza
Amber M D'Souza
RSRachana Shah
Rachana Shah
AGAnita Gupta
Anita Gupta
ATAlexander J Towbin
Alexander J Towbin
MAMaria Alonso
Maria Alonso
JGJames I Geller
James I Geller

29 November 2023 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
ADAmber M D'Souza
Amber M D'Souza
MTMaria Thomas
Maria Thomas
MGManu Gnanamony
Manu Gnanamony
TNThu Hien Nguyen
Thu Hien Nguyen
PAPedro A. de Alarcon
Pedro A. de Alarcon
Background: There remains limited knowledge about the immune response to severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccination in pediatric oncology patients, which is essential to provide counseling and risk adaptation in this vulnerable population. The goal of this study was to understand immunogenicity after vaccination in pediatric oncology patients, and determine if certain clinical factors impacted response.Methods: Patients 0–25 years of age with a diagnosis of cancer and actively receiving therapy were enrolled on study. We excluded patients who were completely vaccinated prior to their cancer diagnosis. Blood samples were collected pre‐vaccination, as well as 2, 4–6, and 8–12 weeks after vaccination. Healthy children who were fully vaccinated enrolled as controls. Clinical data and complete blood counts around time of vaccination were collected. To study B‐ and T‐cell immunity, we measured neutralizing antibodies by enzyme‐linked immunoassay and interferon gamma secretion by enzyme‐linked immunospot, respectively.Results: Twenty‐six patients enrolled on study, for which 11 were evaluable oncology patients and seven were healthy controls. Adequate B‐cell response was seen in 36.4% of patients, and adequate T‐cell response in 77.8% of patients. Numbers were too small to detect differences based on malignancy type. There was no differences in immunity based on absolute lymphocyte count (ALC) or intensity of therapy.Conclusion: Pediatric oncology patients have a suboptimal immune response to SARS‐CoV‐2 vaccination. Booster doses will be imperative to provide optimal protection against COVID‐19; however, blood counts may not be a useful guide to optimize the time of administration.

5 August 2019 in Psycho-Oncology
Verified
Journal Article
Closed access
ADAmber M D'Souza
Amber M D'Souza
KDKatie A. Devine
Katie A. Devine
JRJennifer Reiter‐Purtill
Jennifer Reiter‐Purtill
CGCynthia A. Gerhardt
Cynthia A. Gerhardt
KVKathryn Vannatta
Kathryn Vannatta
RNRobert B. Noll
Robert B. Noll

30 May 2024 in Cancers
Verified
Journal Article
Open access
PDF file
MTMaria Thomas
Maria Thomas
TNThu Hien Nguyen
Thu Hien Nguyen
JDJenny Drnevich
Jenny Drnevich
ADAmber M D'Souza
Amber M D'Souza
PAPedr0 A de Alarcon
Pedr0 A de Alarcon
MGManu Gnanamony
Manu Gnanamony
The disialoganglioside, GD2, is a promising therapeutic target due to its overexpression in certain tumors, particularly neuroblastoma (NB), with limited expression in normal tissues. Despite progress, the intricate mechanisms of action and the full spectrum of the direct cellular responses to anti-GD2 antibodies remain incompletely understood. In this study, we examined the direct cytotoxic effects of the humanized anti-GD2 antibody hu14.18K322A (hu14) on NB cell lines, by exploring the associated cell-death pathways. Additionally, we assessed the synergy between hu14 and conventional induction chemotherapy drugs. Our results revealed that hu14 treatment induced direct cytotoxic effects in CHLA15 and SK-N-BE1 cell lines, with a pronounced impact on proliferation and colony formation. Apoptosis emerged as the predominant cell-death pathway triggered by hu14. Furthermore, we saw a reduction in GD2 surface expression in response to hu14 treatment. Hu14 demonstrated synergy with induction chemotherapy drugs with alterations in GD2 expression. Our comprehensive investigation provides valuable insights into the multifaceted effects of hu14 on NB cells, shedding light on its direct cytotoxicity, cell-death pathways, and interactions with induction chemotherapy drugs. This study contributes to the evolving understanding of anti-GD2 antibody therapy and its potential synergies with conventional treatments in the context of NB.

15 July 2021 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
ADAmber M D'Souza
Amber M D'Souza
Armita BahramiArmita Bahrami
Armita Bahrami
JAJeffrey Akeson
Jeffrey Akeson
TFTim Fahey
Tim Fahey
CMCraig Mitchell
Craig Mitchell
RKRobert King
Robert King